Protara Therapeutics Inc
TARA
Company Profile
Business description
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
Contact
345 Park Avenue South
3rd Floor
New YorkNY10010
USAT: +1 646 844-0337
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
51
Stocks News & Analysis
stocks
Jet fuel price spike weighing on Australian airline profits
Fuel volatility can lead to short-term earnings swings but all players bear the cost almost equally.
stocks
US utilities stocks keep rallying as investors bet on power demand growth
Rising electricity demand from data centers supports earnings growth, but Morningstar analysts say the sector looks less attractive after a sharp rally.
stocks
What did Morningstar subscribers buy and sell during March?
How the most traded shares in March stack up against our analysts views.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,181.10 | 29.10 | -0.32% |
| CAC 40 | 8,273.30 | 54.56 | -0.66% |
| DAX 40 | 24,084.28 | 40.06 | 0.17% |
| Dow JONES (US) | 48,381.05 | 154.94 | -0.32% |
| FTSE 100 | 10,572.77 | 36.29 | -0.34% |
| HKSE | 25,947.32 | 75.00 | 0.29% |
| NASDAQ | 23,867.74 | 228.66 | 0.97% |
| Nikkei 225 | 58,134.24 | 256.85 | 0.44% |
| NZX 50 Index | 13,076.58 | 59.32 | 0.46% |
| S&P 500 | 6,996.80 | 29.42 | 0.42% |
| S&P/ASX 200 | 8,978.70 | 32.70 | -0.36% |
| SSE Composite Index | 4,027.21 | 0.58 | 0.01% |